But the report, on the experiences of 13 patients, found that the drug had no benefit for some people and that some who benefited said the improvement didn’t last.
Category: Paxlovid (Drug)
-
Paxlovid Cuts Covid Death Risk. But Those Who Need It Are Not Taking It.
With Covid deaths rising to about 1,500 per week, researchers question why Paxlovid use has remained low among high-risk patients.
-
How Nursing Homes Failed to Protect Residents From Covid
A series of hurdles prevented the facilities from shielding older people, despite the best efforts of staff. Experts are calling for reforms before the next virus arrives.
-
F.D.A. Advisers Endorse Paxlovid’s Benefits as a Covid Treatment
The New York Times – Business:While an agency analysis did find signs of Covid “rebound,” the drug significantly reduces hospitalizations and deaths, researchers said.
-
China’s Abrupt Covid Pivot Leaves Many Without Medicines
The New York Times – Business:Millions are desperate to get their hands on fever-reducing drugs and antivirals such as Pfizer’s Paxlovid as infections across China outpace supplies.
-
Paxlovid May Reduce Risk of Long Covid in Eligible Patients, Study Finds
The New York Times – Business:The research looked at patients who qualified for the antiviral through age or health conditions. Those who took it shortly after infection were 26 percent less likely to have symptoms 90 days later.